Back to today’s briefing

Story perspectives

120+ Companies Race to Develop Innovative Flu Therapies

8/23/2025

36 5

Summary

Story summary

Over 120 companies are developing new therapies for influenza, including Moderna's mRNA-1010 and SAB Biotherapeutics' SAB-176.
Key candidates focus on severe influenza, featuring a quadrivalent antibody therapy and an intranasal immunomodulatory spray.
The report classifies therapies by administration route and molecule type, highlighting various treatment strategies.

1 of 1

Story summary

Over 120 companies are developing new therapies for influenza, including Moderna's mRNA-1010 and SAB Biotherapeutics' SAB-176.
Key candidates focus on severe influenza, featuring a quadrivalent antibody therapy and an intranasal immunomodulatory spray.
The report classifies therapies by administration route and molecule type, highlighting various treatment strategies.